Skip to main content

Gordon Carl L's Form 4 filing

Tessera Defense & Homeland Security Inc.HLSQ · filed Mar 17, 2023

Accession no.
0000947871-23-000336
Filed
Mar 17, 2023, 4:29 PM ET
Trade date
Feb 27, 2023
Filing delay
18 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $85.3K. It was filed 18 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gordon Carl LCIK 000128293010% Owner
OrbiMed Israel GP Ltd.CIK 000156959010% Owner
OrbiMed Israel BioFund GP Limited PartnershipCIK 000156982110% Owner
Chimovits ErezCIK 000170639910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 27, 2023Common StockPPurchaseAcquired+348,000$0.245+$85,2603,161,489Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 27, 2023Common StockPPurchaseAcquired+1,789,959–F1–1,789,959Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

These shares of the Issuer's common stock and warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant, subject to an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 9.99% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issuance upon exercise of the warrants.

Referenced by the price of 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)